Neumann and Baumgardner in Health Affairs: Balance Needed in Cost-Effectivness Analysis

In a new blog commentary for Health Affairs, PHE’s Peter Neumann and James Baumgardner examine the reasons why application of CEA technologies across different types of healthcare interventions are imbalanced, and suggest some possible ways in which the policies of government and private entities might change to address the issue.

To read the complete blog, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.